Yazar "Ozkok, S." seçeneğine göre listele
Listeleniyor 1 - 20 / 20
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Can we define any marker associated with brain failure in patients with locally advanced non-small cell lung cancer?(Elsevier, 2021) Sert, F.; Cosgun, G.; Yalman, D.; Ozkok, S.Purpose. - To define the factors which may be related to brain metastasis (BM) in patients with locally advanced non-small cell lung cancer (LA-NSCLC) who developed brain metastases after definitive treatment. Patients and methods. - A total of 208 patients with LA-NSCLC, without BM who received definitive radiotherapy (RT) or RT + chemotherapy (CT) between January 2005 and January 2016 were evaluated retrospectively. Platelet, neutrophil, lymphocyte counts, LDH, CRP, Hb levels, neutrophil-to-lymphocyte radio (NLR), platelet-to-lymphocyte radio (PLR), advanced lung cancer inflammation index (ALI) and FDG-PET/CT parameters (SUVmax of the primary tumor and mediastinal lymph nodes), and patient characteristics were evaluated for brain metastasis free survival (BMFS). Results. - Median follow-up duration was 25 months (range: 3-130 months). Cut-off values for platelet, NLR, PLR, LDH, CRP, and Hb were 290 x 103/mu L, 2.6, 198, 468 IU/L, 2.5 mg/dL, and 11.5 g/d1. We defined each parameter as low or high according to the cut-off values. 56 patients (26.9%) developed brain metastases during follow-up. In univariate analysis, high NLR (P=0.001), PLR (P=0.037), LDH (P = 0.028), CRP (P = 0.002) values, value >= 7.5 for lymph nodes (P = 0.005) and low ALI value (P = 0.002) were poor prognostic factors for BMFS. In multivariate analysis, high NLR (P= 0.022), PLR (P= 0.017), CRP (P= 0.006), stage >= IIIB disease (P< 0.001), multi-stational N2 disease (P= 0.036), adenocarcinoma histology (P< 0.001) and SUVmax value >= 7.5 (P = 0.035) were poor prognostic factors for BMFS. Conclusions. - High NLR, PLR, LDH, CRP values, SUVmax values for lymph nodes, and low ALI which indicates high tumor burden were additional prognostic factors besides stage, histology, and lymph node status. (C) 2020 Societe francaise de radiotherapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.Öğe Comparison of Step-and-Shoot IMRT and Different Volumetric Modulated Arc Therapy (VMAT) Techniques for the Treatment of Prostate Cancer(Elsevier Science Inc, 2012) Yalman, D.; Koylu, M.; Tosun, I.; Hazeral, Y. Z.; Olacak, N.; Ozkok, S.Öğe The effect of TAB duration and pelvic RT in prostate cancers with gleason score 8-10: TROG study(Elsevier Ireland Ltd, 2017) Ozyigit, G.; Onal, C.; Igdem, S.; Alicikus, Z. Arican; Iribas, A.; Akin, M.; Yalman, D.; Cetin, I.; Aksu, M. G.; Atalar, B.; Dincbas, F.; Aydin, B.; Sert, F.; Yildirim, C.; Gorken, I. B.; Agaoglu, F. Y.; Korcum, A. F.; Ozkok, S.; Darendeliler, E.; Akyol, F.Öğe Erythropoietin and radiotherapy in lung cancer patients(Imprimatur Publications, 2009) Yurut-Caloglu, V.; Haydaroglu, A.; Ozkok, S.; Yalman, D.; Bolukbasi, Y.Purpose. To evaluate the effectiveness of recombinant human erythropoietin (rhEPO) in relation to low hemoglobin (Hb) level, overall tumor response rates, and rhEPO adverse events in patients with lung cancer undergoing radiotherapy (RT). Patients and methods: Thirteen consecutive patients were included. All of them had measurable tumor before RT 150 IU/kg of rhEPO-alpha or -beta were administered 3 times per week, 7-10 clays before RT. The target Hb value was 13 g/dl. Tumor response was assessed 6 weeks after completion of RT Results: Response to rhEPO was seen 62% (n=8) of the patients. Weekly mean Hb increment was 0.69 g/dl (range 0.42-1). The mean Hb value during R T was 13.2 g/dl (range 9-14.7) in responding patients, and 10.7 g/dl (range 9.7-11.8) in non-responding patients (p=0.005). Overall response rates to RT were significantly higher in responding than in non-responding patients (p=0.034). Conclusion: rhEPO increased Hb levels in lung cancer patients undergoing RT. However, safety, and more importantly, indications need further clarifications.Öğe Geriatric Stage III NSCLC: Which scoring systems could guide us better to predict treatment outcome?(Elsevier Ireland Ltd, 2022) Sert, F.; Farzam, F.; Yalman, D.; Ozkok, S.[No Abstract Available]Öğe HPV Infection and Immunohistochemical Analysis of P16, P53, and PD-L1 Expression as Prognostic Biomarkers in Squamous Cell Anal Cancer Patients Receiving Definitive Radiotherapy/Chemoradiotherapy(Elsevier Science Inc, 2023) Topuz, B. Balcı; Sert, F.; Sezak, M.; Soylu, M.; Yalman, D.; Ozkok, S.[No abstract available]Öğe Lymphopenia and accidental splenic doses for locally advanced gastric cancer(Elsevier Ireland Ltd, 2019) Sert, F.; Yalman, D.; Ozkok, S.Öğe Phase II study of loading-dose ibandronate treatment in patients in breast cancer and bone metastases suffering from moderate to severe pain(Amer Soc Clinical Oncology, 2010) Dizdar, O.; Altundag, M. K.; Ozkok, S.; Ozsaran, Z.; Saip, P.; Eralp, Y.; Komurcu, S.; Kuzhan, O.; Ozguroglu, M.; Karahoca, M.Öğe The plasma cells density in pararectal lymph nodes of patients with rectal cancer after neoadjuvant therapy(Springer, 2012) Sezak, M.; Ozsan, N.; Pehlivanoglu, B.; Ozkok, S.; Yoldas, T.; Daganavsargil, B.Öğe Postoperative adjuvant gemcitabine alone and concurrent with radiation after resection of locally advanced pancreatic carcinoma(Pergamon-Elsevier Science Ltd, 2005) Ozkok, S.; Dubova, S.; Yuzer, Y.; Yalman, D.; Uslu, R.; Coker, A.; Zeytunlu, M.; Goker, E.Öğe Postoperative gemcitabine alone and concurrent with radiation therapy in locally advanced pancreatic carcinoma.(Amer Soc Clinical Oncology, 2010) Demirci, S.; Ozkok, S.; Yalman, D.; Zeytunlu, M.; Nart, D.; Yuzer, Y.; Coker, A.; Uslu, R.; Goker, E.Öğe Prognostic Factors Affecting Brain Metastasis-Free Survival in Non-Small Cell Lung Cancer Patients(Elsevier Science Inc, 2019) Sert, F.; Yalman, D.; Cosgun, G.; Ozkok, S.[No abstract available]Öğe Prognostic Factors for Survival in Patients with Thymic Epithelial Tumors(Georg Thieme Verlag Kg, 2011) Demirci, S.; Turhan, K.; Ozsan, N.; Yalman, D.; Cakan, A.; Cok, G.; Cagirici, U.; Ozkok, S.Background: Aim of the study was to identify and evaluate the prognostic efficacy of standard clinicopathological factors of thymic epithelial tumors (TETs) for treatment-related outcomes. Materials and Methods: All patients treated between 1993-2008 at Ege University Faculty of Medicine Departments of Radiation Oncology and Thoracic Surgery were reviewed retrospectively. Results: Forty-seven patients with a median age of 51 (range: 24-72) were identified. Complete resection was performed in 23 (51.1%), incomplete resection with microscopic residues in 17 (37.8%), subtotal resection with gross residues in 2 (4.4%) and biopsy in 5 (11.1%) patients. Radio-therapy was administered to 39 (83%) patients. Median follow-up duration was 51 months (range: 3-168 months). Five-year local recurrence-free survival (LRFS), disease-free survival (DFS), and overall survival (OS) rates were 93%, 90% and 85% for thymoma and 80%, 66% and 72% for thymic carcinoma patients, respectively. In multivariate analysis, the extent of resection was the only significant prognostic factor for OS (p = 0.001). Conclusions: The most important prognostic factor for overall survival was the extent of resection. Further studies with larger numbers of patients are required to confirm the prognostic factors and to obtain a better understanding of the biological behavior of TETs.Öğe The Prognostic Significance of ERCC1, RRM1, MMP7 and VEGF Expression in Locally Advanced Pancreatic Cancer Patients Treated with Gemcitabine-based Radiochemotherapy(Elsevier Science Inc, 2011) Demirci, S.; Ozkok, S.; Nart, D.; Yalman, D.; Argon, A.; Coker, A.Öğe Prognostic Value of Volumetric PET Parameters in Patients with Locally Advanced Rectal Cancer(Elsevier Ireland Ltd, 2019) Sert, F.; Oral, A.; Savas, R.; Yalman, D.; Ozkok, S.Öğe Radiotherapy for brain metastases: Evaluation of 665 patients(Elsevier Science Inc, 2008) Yalman, D.; Bolukbasi, Y.; Yavas, F.; Ozkok, S.Öğe Randomized clinical trial of short or long interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer(Wiley, 2018) Akgun, E.; Caliskan, C.; Bozbiyik, O.; Yoldas, T.; Sezak, M.; Ozkok, S.; Kose, T.; Karabulut, B.; Harman, M.; Ozutemiz, O.Background: The optimal timing of surgery following preoperative chemoradiotherapy (CRT) is controversial. This trial aimed to compare pathological complete response (pCR) rates obtained after an interval of 8weeks or less versus more than 8weeks. Methods: Patients with locally advanced rectal adenocarcinoma situated within 12cm of the anal verge (T3-4 or N+ disease) were randomized to undergo total mesorectal excision (TME) within 8weeks (classical interval, CI group) or after 8weeks (long interval, LI group) following CRT. Results: Among the 327 included patients (CI 160, LI 167), the pCR rate was significantly higher in the LI group than in the CI group (100 versus 186 per cent; P=0027). The highest pCR rate (29 percent) was observed between 10 and 11weeks. There was statistically significant disease regression in the LI group, with better stage (P=0004) and T category (P=0001) than in the CI group. There was no significant difference in surgical quality (rates of tumour-positive margins, TME quality, anastomotic leakage and intraoperative perforation) between the groups. The overall morbidity rate was 225 per cent in the CI group and 198 per cent in the LI group (P=0307). Regression analysis including sex, age, clinical stage, tumour location, tumour differentiation, TME quality, concomitant chemotherapy and interval to surgery revealed no statistically significant predictors of pCR. Conclusion: Disease regression and pCR rate are increased with an interval between CRT and surgery exceeding 8weeks. Registration number: NCT03287843.Öğe REGIONAL RECURRENCE RATES OF STAGE I ENDOMETRIAL CARCINOMA PATIENTS TREATED WITH ADJUVANT BRACHYTHERAPY(Lippincott Williams & Wilkins, 2017) Alanyali, S.; Sert, F.; Gocen, F.; Temel, O.; Ozsaran, Z.; Yildirim, N.; Solmaz, U.; Gokcu, M.; Akman, L.; Terek, C.; Ozsaran, A.; Sanci, M.; Yildiz, H. I.; Ozkok, S.; Aras, A.Öğe REGIONAL RECURRENCE RATES OF STAGE I ENDOMETRIAL CARCINOMA PATIENTS TREATED WITH ADJUVANT BRACHYTHERAPY(Lippincott Williams & Wilkins, 2017) Alanyali, S.; Sert, F.; Gocen, F.; Temel, O.; Ozsaran, Z.; Yildirim, N.; Solmaz, U.; Gokcu, M.; Akman, L.; Terek, C.; Ozsaran, A.; Sanci, M.; Yildiz, H. I.; Ozkok, S.; Aras, A.Öğe Results of hypofractionated whole brain radiotherapy (2x8 Gy) for patients with brain metastases from lung cancer(Zerbinis Medical Publ, 2011) Ozkok, S.; Bolukbasi, Y.; Akcay, C. Akay; Yalman, D.Purpose: To evaluate the clinical and radiologic response rates, toxicity and tolerability of 2x8 Gy whole brain radiotherapy (WBRT) in lung cancer patients with brain metastases (BM). Methods: WBRT was delivered to 126 lung cancer patients with BM during 2002-2006. External beam RT was delivered with a fraction dose of 8 Gy on the same day of each consecutive week Tumor and symptom response and toxicity were recorded at every follow-up. Recursive partitioning analysis (RPA) and the new Graded Prognostic Assessment (GPA) were used for analysis of overall survival (OS). Results: Twenty-three patients had small cell (SCLC) and 103 had non small cell lung cancer Pretreatment median Karnofsky performance score (KPS) was 70 (range 20-90). Clinical response rates were as follows: complete 31%; good partial 30.2%; partial 21.4%; stable 7.9%; and progressive 5.6%. Median palliation and survival duration was 57 and 80 days, respectively. Two- and 6-month survival rates (SR) were 59.5% and 25.4%, respectively. According to recursive partitioning analysis (RPA) 6-month SR for groups 1, 2 and 3 were 61.5, 41.6 and 33.9%, respectively (p=0.002). Six-month SR for the new Graded Prognostic Assessment (GPA) were: GPA 0-1, 7%; GPA 1.5-2.5, 34.2%; GPA 3, 25%; and GPA 3.5-4.0, 66.6% (p=0.0003). Conclusion: 2x8 Gy WBRT was found to be feasible. However the late morbidity of this schedule is unknown so its use could be restricted to patients with poor performance status, with a short life expectancy and/or social problems, unlikely to tolerate more protracted radiotherapy regimens.
